Clinical validation FDA-cleared at-home treatment for panic disorder and PTSD presents a strong case for partnerships with health plans, employers, and veteran organizations seeking proven, non-drug solutions to reduce medical spend and improve quality of life.

Expansion-ready device Recent launches of the 5th generation Freespira device and sensor integration create a compelling cross-sell opportunity with healthcare providers and payers looking for the latest technology to enhance patient engagement and treatment efficacy.

Strategic partnerships Existing collaborations with Lovell Government Services and healthcare plans indicate a validated channel to reach Veterans and insured populations; leverage these relationships to expand adoption in public and private sectors.

Financial momentum With notable funding of around $44M and revenue in the low to mid single digits, there is appetite and capacity to scale field deployments, clinical studies, and payer negotiations to accelerate growth.

Recognition advantage Being named to Fast Company's World’s Most Innovative Companies list enhances credibility with buyers and can be used in outreach to accelerate interest from health systems, employers, and government programs.